Company profile
VERA THERAPEUTICS, INC.
NASDAQ:VERABiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TRUTAKNA | approved | — | 0 | — |
| TRAXIVITUG | phase2 | — | 2 | completed, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06674577 | phase2 | enrolling_by_invitation | 2024-12-01 | 2031-05-21 | Vera Therapeutics, Inc. | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept |
| NCT04294472 | phase2 | completed | 2020-08-05 | 2022-02-10 | Vera Therapeutics, Inc. | A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients |
| NCT06983028 | phase2 | recruiting | 2025-07-07 | 2027-11-01 | Vera Therapeutics, Inc. | Atacicept in Multiple Glomerular Diseases |
| NCT05609812 | phase3 | withdrawn | 2022-11-02 | 2026-03-15 | Vera Therapeutics, Inc. | Atacicept in Subjects With Active Lupus Nephritis (COMPASS) |
| NCT04716231 | phase3 | active_not_recruiting | 2023-06-29 | 2025-05-15 | Vera Therapeutics, Inc. | Atacicept in Subjects With IgA Nephropathy |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761486 | 2026-07-07 | BLA | VERA THERAPEUTICS, INC. | |||||
Loading… | ||||||||